Skip to main content
Article thumbnail
Location of Repository

Results of the MRI substudy of the intravenous magnesium efficacy in stroke trial

By C.S. Kidwell, K.R. Lees, K.W. Muir, C. Chen, S.M. Davis, D.A. De Silva, C.J. Weir, S. Starkman, J.R. Alger and J.L. Saver

Abstract

<p><b>Background and Purpose:</b>Although magnesium is neuroprotective in animal stroke models, no clinical benefit was confirmed in the Intravenous Magnesium Efficacy in Stroke (IMAGES) trial of acute stroke patients. The Magnetic\ud Resonance in IMAGES (MR IMAGES) substudy investigated the effects of magnesium on the imaging surrogate\ud outcome of infarct growth.</p>\ud \ud <p><b>Methods:</b> IMAGES trial patients in participating centers were randomized to receive either intravenous magnesium or placebo within 12 hours of stroke onset. Infarct growth was defined as volume difference between baseline diffusion-weighted imaging and day 90 fluid-attenuated inversion recovery image lesions. Patients who died were imputed the largest infarct growth observed.</p>\ud \ud <p><b>Results:</b> Among the 90 patients included in the primary analysis, there was no difference in infarct growth (median absolute growth, P=0.639; median percentage growth, P=0.616; proportion with any growth, P=0.212) between the\ud 46 treated with magnesium and 44 with placebo. Infarct growth correlated with NIHSS score change from baseline to\ud day 90. There was a trend showing baseline serum glucose correlated with infarct growth with magnesium treatment,\ud but not in the placebo group. The mismatch frequency was reduced from 73% to 47% by increasing the mismatch\ud threshold from >20% to >100% of core volume.</p>\ud \ud <p><b>Conclusions:</b> Infarct growth, confirmed here as a surrogate for clinical progression, was similar between magnesium and placebo treatment, paralleling the main IMAGES trial clinical outcomes. Glucose was a covariate for infarct growth with magnesium treatment. A more stringent mismatch threshold to define penumbra more appropriately would have\ud excluded half of the patients in this 12-hour time window stroke study.</p&gt

Publisher: American Heart Association
Year: 2009
OAI identifier: oai:eprints.gla.ac.uk:18551
Provided by: Enlighten

Suggested articles

Citations

  1. (1995). A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke.
  2. (1995). Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging. Ann Neurol.
  3. (2002). Acute hyperglycemia adversely affects stroke outcome: A magnetic resonance imaging and spectroscopy study. Ann Neurol.
  4. Beyond mismatch: Evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging.
  5. Classification and natural history of clinically identifiable subtypes of cerebral infarction.
  6. (2002). Diffusionand perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol.
  7. Does the mismatch match the penumbra? Magnetic resonance imaging and positron emission tomography in early ischemic stroke.
  8. Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset.
  9. Dose optimization of intravenous magnesium sulfate after acute stroke.
  10. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke 6 hours.
  11. (2008). Effects of alteplase beyond 3 h after stroke in the echoplanar imaging thrombolytic evaluation trial (EPITHET): A placebocontrolled randomised trial. Lancet Neurol.
  12. (1998). Images pilot study of intravenous magnesium in acute stroke. Cerebrovasc Dis.
  13. Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials. The RANTTAS Investigators.
  14. Influence of pretreatment MRI parameters on clinical outcome, recanalization and infarct size in 49 stroke patients treated by intravenous tissue plasminogen activator.
  15. (1984). Infusion of magnesium in patients with acute brain infarction. Acta Neurol Scand.
  16. (2001). Intravenous administration of magnesium sulfate in acute stroke: A randomized double-blind study. Clin Neuropharmacol.
  17. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study.
  18. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): Randomised controlled trial.
  19. Magnesium for treatment of acute lacunar stroke syndromes: Further analysis of the images trial.
  20. Magnesium in stroke treatment.
  21. (1990). Magnesium reduces n-methyl-d-aspartate (NMDA)-mediated brain injury in perinatal rats. Neurosci Lett.
  22. (2006). Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol.
  23. (2008). Magnetic resonance in intravenous magnesium efficacy in stroke trial:
  24. (1991). Mg2 administered up to twenty-four hours following reperfusion prevents ischemic damage of the ca1 neurons in the rat hippocampus.
  25. (1996). Neuroprotective effects of preischemia intraarterial magnesium sulfate in reversible focal cerebral ischemia.
  26. (2001). New imaging strategies for patient selection for thrombolytic and neuroprotective therapies.
  27. Optimal definition for PWI/DWI mismatch in acute ischemic stroke patients.
  28. Persistent poststroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome.
  29. Prediction of early neurological deterioration using diffusion- and perfusion-weighted imaging in hyperacute middle cerebral artery ischemic stroke.
  30. Proof-of-principle phase II MRI studies in stroke: Sample size estimates from dichotomous and continuous data.
  31. (1991). Reduction of infarct volume by magnesium after middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab.
  32. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: A systematic overview.
  33. Stroke Therapy Academic Industry Roundtable. Recommendations for standards regarding preclinical neuroprotective and restorative drug development.
  34. The desmoteplase in acute ischemic stroke trial (DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase.
  35. (1999). The DWI/PWI mismatch region in acute stroke.
  36. (2008). The past and future of neuroprotection in cerebral ischaemic stroke. Eur Neurol.
  37. The use of PWI and DWI measures in the design of “Proof-of-concept” Stroke trials.
  38. Trends in acute ischemic stroke trials through the 20th century.
  39. Which MR-derived perfusion parameters are the best predictors of infarct growth in hyperacute stroke? Comparative study between relative and quantitative measurements.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.